�Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from an ongoing Phase I/II clinical trial of ispinesib are scheduled to be presented as a posting presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September fifty-seven, 2008 at the Hilton Washington in Washington, DC.
In June 2008, as part of a post horse session at the ASCO Annual Meeting, Cytokinetics announced interim data from the Phase I portion of its ongoing Phase I/II clinical trial of ispinesib, a novel kinesin spindle protein (KSP) inhibitor, administered as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally advanced or metastatic breast cancer the Crab. The authors concluded that preliminary data suggest that ispinesib is well-tolerated when dosed on days 1 and 15 every 28 days at doses up to 12 mg/m2. Results from additional patients enrolled in the ongoing Phase I, dose-escalation portion of this clinical trial ar scheduled to be presented the 2008 ASCO Breast Cancer Symposium.
Poster Presentation at ASCO Breast Cancer Symposium
Abstract #192: "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein (KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated with Chemotherapy (CT) for Metastatic Disease or Recurrence." (Poster Presentation on Friday, September 5, 2008, during the General Poster Session, 5:30 pm - 6:45 pm Eastern Time). The poster will be found in the Exhibit Hall at poster board #A50 and presented by Henry Gomez, MD from Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima, Peru.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small atom drugs that may speak areas of significant unmet clinical necessarily. Cytokinetics' cardiovascular disease broadcast is focussed to cardiac myosin, a motor protein essential to cardiac musculus contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. ar performing reefer research focused on identifying and characterizing activators of cardiac myosin as computer backup and follow-on potential drug candidates to CK-1827452. Amgen has obtained an selection for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial involvement rights. Cytokinetics' cancer computer programme is focussed on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) ar conducting enquiry and development activities focused on the potential handling of cancer. Cytokinetics is developing 2 novel dose candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is sponsoring a Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally modern or metastatic breast malignant neoplastic disease. In addition, Cytokinetics is conducting a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphomas. GSK has obtained an option for the joint development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategical alliance by GSK; GSK began a Phase I clinical tribulation with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a electric potential drug candidate directed towards skeletal muscle contractility which may be developed as a electric potential treatment for skeletal musculus weakness associated with neuromuscular diseases or other weather condition. All of these drug candidates and potential drug candidates experience arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a composite biological infrastructure that plays a profound role inside every human cell. Additional information around Cytokinetics can be obtained at hypertext transfer protocol://www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intention or debt instrument to update these innovative statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, merely are non limited to, statements relating to Cytokinetics' research and development programs, including planned presentations relating to clinical trial results, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, electric potential difficulties or delays in the development, testing, regulatory approval or production of Cytokinetics' drug candidates that could slow or keep clinical evolution or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutical efficacy, the U.S. Food and Drug Administration or foreign regulative agencies english hawthorn delay or limit Cytokinetics' or its partners' ability to direct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur unforeseen research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change and others may introduce products or alternative therapies for the handling of indications Cytokinetics' do drugs candidates and potential dose candidates may target; and risks and uncertainties relating to the timing and receipt of payments from Cytokinetics' partners, including milestones and royalties on future potential product sales under its collaborationism agreements with such partners. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Cytokinetics
More info
Subscribe to:
Posts (Atom)